Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$56.30 USD
+2.01 (3.70%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $55.99 -0.31 (-0.55%) 6:08 PM ET
3-Hold of 5 3
C Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GPCR 56.30 +2.01(3.70%)
Will GPCR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
IPO Round Up of First Half of 2023
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for GPCR
Structure Therapeutics' Slim Obesity Hopes In A Pill Take Shape
Qiming's Nisa Leung Made the 2024 Forbes Midas List
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
Analysts’ Top Healthcare Picks: Formycon AG (DE:FYB), Novartis AG (CH:NOVN)
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants